Volume 19, Number 3—March 2013
Research
Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. Meltzer
Table 1
Data used to calculate effects of vaccination program against influenza A(H1N1)pdm09 virus by population subgroup*
| Subgroup | Population | % Vaccinated | No. doses recommended for full coverage | % Assumed outcomes |
||
|---|---|---|---|---|---|---|
| Vaccine effectiveness† | Clinical cases and hospitalizations | Deaths | ||||
| 6 mo–9 y | 39,429,115 | 1st dose/45, 2nd dose/23 | 2 doses, 4 wks apart | 1st dose/0, 2nd dose/62 | 20.1 | 6.0 |
| 10–24 y (10–17 all, 18–24 NP) | 59,684,833 | 27 | 1 | 62 | 22.3 | 8.0 |
| Pregnant 18–64 y | 5,578,782 | 43 | 1 | 62 | 2.2 | 4.0 |
| 25–64 y, HR, NP | 33,949,395 | 27 | 1 | 62 | 13.5 | 24.0 |
| 25–64 y, HCW, non-HR, NP | 17,451,921 | 36 | 1 | 62 | 5.6 | 9.0 |
| 25–64 y, contact <6 mo, non-HCW, non-HR, NP | 8,933,718 | 23 | 1 | 62 | 2.5 | 6.0 |
| 25–64 y, non-contact <6 mo, non-HCW, non-HR, NP | 96,235,755 | 16 | 1 | 62 | 24.0 | 30.0 |
| >65 y |
37,989,965 |
28 |
1 |
43 |
9.8 |
13.0 |
| Total |
299,253,484 |
27 |
1–2 |
NA |
NA |
NA |
| References | (14,28,39) | (9,14,28) | (6) | (24,36,40) | (2,19–21) | (2,19–21) |
*NP, not pregnant; HR, high risk; HCW, health care worker; contact, household contacts and caregivers of children <6 months of age; NA, not applicable.
†Data are for effectiveness against clinical cases, hospitalizations, and deaths. For population subgroup 6 mo–9 y, we assumed the vaccine reached effectiveness levels 2 wk after full coverage (12).
1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.
